A phase i trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Chilengi, Roma ^a   Juma, Rashid ^a   Abdallah, Ahmed M ^a   Bashraheil, Mahfudh ^a   Lodenyo, Hudson ^a   Nyakundi, Priscilla ^a   Anabwani, Evelyn ^a   Salim, Amina ^a   Mwambingu, Gabriel ^a   Wenwa, Ednah ^a   Jemutai, Julie ^a   Kipkeu, Chemtai ^a   Oyoo, George O ^b   Muchohi, Simon N ^a   Kokwaro, Gilbert ^c   Niehues, Tim ^d   Lang, Trudie ^e   Nzila, Alexis ^a,f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c Kenyatta National Hospital ^*  (Kenya)

^d HELIOS KLINIKUM KREFELD   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD SAMPLING; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; FOLLOW UP; HUMAN; KENYA; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH ULCER; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN EXPERIMENT; MALARIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIMALARIALS; BLOOD CHEMICAL ANALYSIS; HUMAN EXPERIMENTATION; HUMANS; KENYA; MALARIA; MALE; METHOTREXATE;

EID: 79952705886     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-63     Document Type: Article

References (36)

1. Medicines for malaria venture (MMV) research, development and science-portfolio. http://www.mmv.org/research-development/science-portfolio
2. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. AM Dondorp CI Fanello IC Hendriksen E Gomes A Seni KD Chhaganlal K Bojang R Olaosebikan N Anunobi K Maitland E Kivaya T Agbenyega SB Nguah J Evans S Gesase C Kahabuka G Mtove B Nadjm J Deen J Mwanga-Amumpaire M Nansumba C Karema N Umulisa A Uwimana OA Mokuolu OT Adedoyin WB Johnson AK Tshefu MA Onyamboko T Sakulthaew WP Ngum K Silamut K Stepniewska CJ Woodrow D Bethell B Wills M Oneko TE Peto L von Seidlein NP Day NJ White, Lancet 2010 376 1647 1657 10.1016/S0140-6736(10)61924- 1 21062666
3. Artemisinin resistance in Plasmodium falciparum malaria. AM Dondorp F Nosten P Yi D Das AP Phyo J Tarning KM Lwin F Ariey W Hanpithakpong SJ Lee P Ringwald K Silamut M Imwong K Chotivanich P Lim T Herdman SS An S Yeung P Singhasivanon NP Day N Lindegardh D Socheat NJ White, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
4. Update on genetic markers of quinine resistance in Plasmodium falciparum. J Okombo E Ohuma S Picot A Nzila, Mol Biochem Parasitol 2011 21295079
5. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. SM Kiara J Okombo V Masseno L Mwai I Ochola S Borrmann A Nzila, Antimicrob Agents Chemother 2009 53 3793 3798 10.1128/AAC.00308-09 19528269
6. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. O Dar MS Khan I Adagu, Jpn J Infect Dis 2008 61 210 211 18503171 (Pubitemid 351888592)
7. 2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. E Nduati S Hunt EM Kamau A Nzila, Antimicrob Agents Chemother 2005 49 3652 3657 10.1128/AAC.49.9.3652-3657. 2005 16127035 (Pubitemid 41233013)
8. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. DA Fidock T Nomura TE Wellems, Mol Pharmacol 1998 54 1140 1147 9855645 (Pubitemid 29002060)
9. Pyrimethamin-resistant Plasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines. RD Walter B Bergmann M Kansy M Wiese JK Seydel, Parasitol Res 1991 77 346 350 10.1007/BF00930913 1866423
10. Antineoplastic agents. BA Chabner P Amrein B Drucker M Michealson C Mitsiades P Goss D Ryan S Ramachandra P Richardson J Supko W Wilson, The pharmacological basis of therapeutics 9/e New York: McGrwa-Hill, Brunton L, 2006 1315 1465
11. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. RE Kalb B Strober G Weinstein M Lebwohl, J Am Acad Dermatol 2009 60 824 837 10.1016/j.jaad.2008.11.906 19389524
12. Methotrexate in rheumatoid arthritis. J Swierkot J Szechinski, Pharmacol Rep 2006 58 473 492 16963793 (Pubitemid 44383273)
13. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. T Niehues P Lankisch, Paediatric drugs 2006 8 347 356 10.2165/00148581-200608060-00003 17154642 (Pubitemid 44912719)
14. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. J Chladek J Grim J Martinkova M Simkova J Vaneckova, Basic Clin Pharmacol Toxicol 2005 96 247 248 10.1111/j.1742-7843. 2005.pto960318.x 15733224 (Pubitemid 40388005)
15. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. J Grim J Chladek J Martinkova, Clin Pharmacokinet 2003 42 139 151 10.2165/00003088-200342020-00003 12537514 (Pubitemid 36188554)
16. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. J Chladek J Grim J Martinkova M Simkova J Vaniekova V Koudelkova M Noiekova, Br J Clin Pharmacol 2002 54 147 156 10.1046/j.1365-2125. 2002.01621.x 12207634 (Pubitemid 35024938)
17. Methotrexate in the therapy of malaria. A Wildbolz, Ther Umsch 1973 30 218 222 4569629
18. Methotrexate therapy for Plasmodium vivax malaria. TW Sheehy H Dempsey, Jama 1970 214 109 114 10.1001/jama.214.1.109 4918156
19. Anticancer agents against malaria: time to revisit? A Nzila J Okombo RP Becker R Chilengi T Lang T Niehues, Trends Parasitol 2010 26 125 129 10.1016/j.pt.2009.12.002 20056487
20. World Medical Association Declaration of Helsinki: ethical principles from medical tresearch involving human subjects. Anonymous, Paragraph 17. Revision adopted by the 59th World Medical Assembly, Seoul 2008
21. International Conference on Harmonisation Guidance: Good Clinical Practices. Global Medical Education & Development. ICH-GCP-E6, 1997 http://www.icr-global.org
22. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. K Visser DM van der Heijde, Clin Exp Rheum 2009 27 1017 1025
23. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. MR Fournier J Klein GY Minuk CN Bernstein, Am J Gastroenterol 2010 105 1620 1626 10.1038/ajg.2010.21 20160715
24. [Therapeutic maintenance level of methotrexate in rheumatoid arthritis]. L Tahiri F Allali I Jroundi R Abouqal N Hajjaj-Hassouni, Sante 2006 16 167 172 17284392
25. Socio-demographic and clinical aspects of rheumatoid arthritis. BO Owino GO Oyoo CF Otieno, East Afr Med J 2009 86 204 211 20084988
26. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. E Domenech M Manosa M Navarro H Masnou E Garcia-Planella Y Zabana E Cabre MA Gassull, J Clin Gastroent 2008 42 395 399 10.1097/MCG. 0b013e31802e6875 18277899 (Pubitemid 351450625)
27. [Autoimmune urticaria. Treatment with methotrexate]. P Montero Mora C Gonzalez Perez Mdel V Almeida Arvizu JJ Matta Campos, Rev Alerg Mex 2004 51 167 172 15794405
28. Is methotrexate effective for the treatment of ankylosing spondylitis? J Chen, Nature Clin Pract 2007 3 490 491 10.1038/ncprheum0566 (Pubitemid 47351391)
29. Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature. T Bosman C Simonin D Launay S Caron A Destee L Defebvre, Rheum Intern 2008 28 713 718 10.1007/s00296-007-0504-5
30. Role of methotrexate in the treatment of chronic cholestatic disorders. K Novak MG Swain, Clinics Liv Dis 2008 12 81 96 10.1016/j.cld.2007.11.011 (Pubitemid 351175656)
31. Methotrexate for Wegener's granulomatosis: what is the evidence? U Specks, Arthritis Rheum 2005 52 2237 2242 10.1002/art.21146 16052540 (Pubitemid 41117404)
32. Methotrexate for primary biliary cirrhosis. Y Gong C Gluud, Cochrane Database Syst Rev 2005 D004385 16034929
33. Methotrexate in systemic lupus erythematosus. JM Wong JM Esdaile, Lupus 2005 14 101 105 10.1191/0961203305lu2043rr 15751813 (Pubitemid 40327659)
34. Methotrexate in inflammatory eye disease. R Stawell, Oc Immunol Inflam 2003 11 79 82 10.1076/ocii.11.2.79.15918 (Pubitemid 37088579)
35. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. JI Henter A Horne M Arico RM Egeler AH Filipovich S Imashuku S Ladisch K McClain D Webb J Winiarski G Janka, Pediat Blood Cancer 2007 48 124 131 10.1002/pbc.21039 (Pubitemid 44958267)
36. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. E Nduati A Diriye S Ommeh L Mwai S Kiara V Masseno G Kokwaro A Nzila, Parasitol Res 2008 102 1227 1234 10.1007/s00436-008-0897-4 18259776